

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 209/16, A61K 31/33 C07D 401/12, 403/12, 453/02 C07D 221/22, 409/12, 213/56		A1	(11) International Publication Number: WO 94/01402 (43) International Publication Date: 20 January 1994 (20.01.94)
(21) International Application Number: PCT/GB93/01415		(74) Agent: QUILLIN, Helen, Kaye; Merck & Co., Inc., European Patent Department, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).	
(22) International Filing Date: 6 July 1993 (06.07.93)		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority data: 9214864.2 13 July 1992 (13.07.92) GB 9222175.3 22 October 1992 (22.10.92) GB 9226070.2 14 December 1992 (14.12.92) GB 9304398.2 4 March 1993 (04.03.93) GB		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only) : LEWIS, Richard, Thomas [GB/GB]; 52 Byngams, Harlow, Essex CM19 5NS (GB). MACLEOD, Angus, Murray [GB/GB]; 24 Abbotts Way, Thorley Park, Bishops Stortford, Hertfordshire CM23 4YE (GB). MERCHANT, Kevin, John [GB/GB]; 29 Red Lion Court, Dane Street, Bishops Stortford, Hertfordshire CM23 3IL (GB).			

(54) Title: HETEROCYCLIC AMIDE DERIVATIVES AS TACHYKININ DERIVATIVES



(57) Abstract

Compounds of formula (I), and salts and prodrugs thereof, wherein Q¹ is phenyl substituted by one or more halo; optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl; the dotted line represents an optional covalent bond; one of X and Y is H and the other is hydroxy or C₁₋₆alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁₋₆alkyl; R¹ is H or C₁₋₆alkyl. R² is CO-W-R⁶ where W represents a bond or a hydrocarbon chain of 1-6 carbon atoms and R⁶ is an azacyclic or azabicyclic group; R³ is H, C₁₋₆alkyl or C₂₋₆alkenyl; and R⁴ is phenyl optionally substituted by 1-3 of C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are H, C₁₋₆alkyl, phenyl or trifluoromethyl; are tachykinin antagonists useful in therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 1 -

HETEROCYCLIC AMIDE DERIVATIVES AS TACHYKININ DERIVATIVES

5 This invention relates to a class of heterocyclic compounds, which are useful as tachykinin receptor antagonists.

10 The tachykinins are a group of naturally-occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in the peripheral nervous and circulatory systems. The structures of three known mammalian tachykinins are as follows:

Substance P:

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂

15 Neurokinin A:

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH₂

Neurokinin B:

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH₂

20 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy, 25 irritable bowel syndrome and disorders of bladder function including cystitis and bladder detrusor hyperreflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R. Patacchini, P. Rovero and A. Giachetti, J. Auton.

- 2 -

Pharmacol. (1993) 13, 23-93. Tachykinin antagonists are also believed to be useful in allergic conditions (Hamelet et al Can. J. Pharmacol. Physiol. (1988) 66 1361-7], immunoregulation [Lotz et al Science (1988) 241 1218-21 and Kimball et al, J. Immunol. (1988) 141 (10) 3564-9], and as anticonvulsants [Garant et al., Brain Research (1986) 382 372-8]. Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al., Cancer Research (1992) 52, 4554-7].

It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliisis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosis (European patent application no. 0 436 334), conjuctivitis, vernal conjunctivitis, contact dermatitis, atropic dermatitis, urticaria, and other eczematoid dermatitis (European patent application no. 0 394 989) and emesis (European patent application no. 0 533 280).

Peptide tachykinin antagonists containing an indolyl or like moiety are disclosed in European patent applications nos. 0 394 989 and 0 482 539.


In view of their metabolic instability, peptide derivatives are likely to be of limited utility as therapeutic agents. It is for this reason that non-peptide tachykinin receptor antagonists are sought.

- 3 -

In essence, this invention provides a class of potent non-peptide tachykinin receptor antagonists.

The present invention provides a compound of formula (I), or a salt or prodrug thereof:

5



(I)

15 wherein

Q¹ represents a phenyl group substituted by one or more halo; optionally substituted naphthyl; optionally substituted indolyl; optionally substituted benzothiophenyl; optionally substituted benzofuranyl; 20 optionally substituted benzyl; or optionally substituted fluorenyl;

the dotted line represents an optional covalent bond;

one of X and Y represents H and the other of X 25 and Y represents hydroxy or C₁₋₆alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁₋₆alkyl;

R¹ represents H or C₁₋₆alkyl.

R² represents CO-W-R⁶ where W represents a bond 30 or a saturated or unsaturated hydrocarbon chain of 1, 2, 3, 4, 5 or 6 carbon atoms and R⁶ is an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R³ represents H, C₁₋₆alkyl or C₂₋₆alkenyl; and

- 4 -

5 R^4 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_1 - α alkyl, C_2 - α alkenyl, C_2 - α alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_1 - α alkyl, phenyl or trifluoromethyl.

10 For the avoidance of doubt, when the covalent bond represented by the dotted line is present, the compounds of formula (I) contain an olefinic double bond.

15 As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

20 15 The alkyl, alkenyl and alkynyl groups referred to with respect to any of the above formulae may represent straight, branched or cyclic groups or combinations thereof. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl, n-, sec-, iso- or tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and cycloalkyl-alkyl groups such as cyclopropylmethyl; suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

25 The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

30 25 When w represents a hydrocarbon chain of 2 or more carbon atoms, it may be straight or branched.

Where Q^1 represents optionally substituted fluorenyl, the fluorenyl group is linked through the bridgehead carbon atom, that is to say, C-9.

35 30 Where Q^1 represents optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl, suitable substituents include C_1 - α alkyl, C_2 - α alkenyl, C_2 - α alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, SR^a , SOR^a , SO_2R^a , OR^a ,

- 5 -

NR^aR^b, NR^aCOR^b, NR^aCOOR^b, COOR^a or CONR^aR^b, where R^a and R^b are as above defined. One or more substituents may be present and each may be located at any available ring position, except, where Q¹ is optionally substituted
5 indolyl, the nitrogen atom. Where Q¹ is optionally substituted indolyl, suitable nitrogen substituents include C₁-6alkyl, optinally substituted phenyl(C₁-4alkyl), COOR^a or CONR^aR^b, wherein R^a and R^b are as above defined.

10 Suitable values of the group Q¹ include dihalophenyl such as 3,4-dichlorophenyl, indolyl such as 3-indolyl, naphthyl such as 2-naphthyl and 3-naphthyl, 9-fluorenyl, benzyl, benzothiophenyl such as 3-benzothiophenyl and benzofuranyl such as 3-benzofuranyl.

15 Preferably Q¹ is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl, more preferably 3-indolyl.

Preferably the double bond is absent.

20 Preferably one of X and Y represents C₁-6alkoxy, such as methoxy, or X and Y together represent =O. More preferably X and Y together represent =O.

Preferably R¹ is H.

Suitable values for W include a bond, CH₂, CH₂CH₂, CH=CH, CH₂CH₂CH₂ and CH₂CH₂CH₂CH₂.

25 In one subgroup of compounds according to the invention, R² represents CO(CH₂)_qR⁶, where q is 0, 1, 2, 3, 4, 5 or 6 and R⁶ is as previously defined.

30 The aromatic or non-aromatic azacycle or azabicycle R⁶ may contain one or more additional heteroatoms selected from N, O and S, or groups NR⁷, where R⁷ is H or C₁-6alkyl, and may be unsubstituted or substituted. Suitable substituents include C₁-6alkyl, C₁-6alkoxy, oxo, SH, =S, halo, trifluoromethyl, NR^aR^b,

- 6 -

NR^aCOR^b, CONR^aR^b, CO₂R^a and CH₂OR^a, where R^a and R^b are as previously defined.

When R⁶ represents an aromatic azacycle or azabicycle, suitable values of R⁶ include imidazolyl, 5 triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl and indolyl, preferably imidazolyl, such as 2,4-imidazolyl, or pyridyl, more preferably pyridyl such as 10 4-, 3- or 2-pyridyl.


When R⁶ represents a non-aromatic azacycle or azabicycle, suitable values of R⁶ include morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorbornanyl, 3,4-pyridinecarboximido, 15 azabicyclo[2.2.2]octanyl and azabicyclo[3.2.2]nonyl, preferably morpholinyl, piperazinyl, methylpiperazinyl, piperidinyl, pyrrolidinyl, 3,4-pyridinecarboximido, quinuclidinyl (azabicyclo[2.2.2] octanyl) or azabicyclo[3.2.2]nonyl.

Preferably R⁴ represents substituted phenyl. 20 Suitable phenyl substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, t-butyl, vinyl, methoxy, phenoxy and amino. Suitably R⁴ represents monosubstituted phenyl, such as 3-substituted phenyl, or, 25 preferably, disubstituted phenyl, such as 3,5-disubstituted phenyl. When R⁴ is 3-substituted phenyl, a particularly suitable substituent is t-butyl. More preferably, R⁴ represents phenyl substituted by 1 or 2 groups selected from C₁₋₄alkyl, halo and trifluoromethyl. 30

Particularly preferred are compounds wherein R⁴ represents 3,5-bis(trifluoromethyl)phenyl.

- 7 -

A particular subgroup of compounds according to the invention is represented by compounds of formula (Ia), and salts and prodrugs thereof:



(Ia)

wherein X and Y are as defined for formula (I);

15 the dotted line represents an optional covalent bond;

20 Z represents O , S or NR^{14} (where R^{14} is H , $\text{C}_1\text{-6alkyl}$, optionally substituted phenyl($\text{C}_1\text{-4alkyl}$), CO_2R^a or CONR^aR^b , where R^a and R^b are as previously defined), preferably S or NH , more preferably NH ;

25 R^{10} is CO-W-R^{16} where R^{16} is imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl, indolyl, morpholinyl, piperdinyl, pyrrolidinyl, pyridosuccinimido, piperazinyl, methylpiperazinyl, azanorboranyl, azabicyclo[2.2.2]octanyl or 30 azabicyclo[3.2.2]nonyl, preferably imidazolyl, pyridyl, morpholinyl, methylpiperazinyl, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl and W is as previously defined, preferably a bond or a hydrocarbon chain of 1, 2 or 3 carbon atoms;

35 R^{11} and R^{12} each independently represent H , $\text{C}_1\text{-6alkyl}$, $\text{C}_2\text{-6alkenyl}$, $\text{C}_2\text{-6alkynyl}$, halo, cyano, nitro,

- 8 -


trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined;

each R¹³ may occupy any available carbon atom of the bicyclic ring system and independently represents C₁-6alkyl, C₂-6alkenyl, C₂-6alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined; and

n is 0, 1, 2 or 3, preferably 0.

Preferred are compounds of formula (Ia) wherein the optional covalent bond is absent.

A further subgroup of compounds according to the invention is represented by compounds of formula (Ib), and salts and prodrugs thereof:



(Ib)

wherein R³, R¹⁰, R¹¹, R¹², X and Y are as previously defined and the dotted line represents an optional covalent bond.

For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a

- 9 -

pharmaceutically acceptable non-toxic acid such as hydrochloric acid, sulphuric acid, oxalic acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Thus, for example, when both R^1 and R^2 are other than hydrogen, the nitrogen atom to which they are attached may be further substituted to give a quaternary ammonium salt. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The present invention accordingly provides compounds of formula (I) and their pharmaceutically acceptable salts.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The compounds according to the invention may exist both as enantiomers and as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

- 10 -

The substance P antagonising activity of the compounds described herein was evaluated using the human NK1R assay described in published European patent application no. 0 528 495. The method essentially 5 involves determining the concentration of the test compound required to reduce by 50% the amount of radiolabelled substance P binding to human NK1R, thereby affording an IC₅₀ value for the test compound. The compounds of Examples 1-10, for example, were found to 10 have IC₅₀ values less than 100nM.

The invention also provides pharmaceutical compositions comprising a compound of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms 15 such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or topical administration including administration by inhalation or insufflation.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium 20 stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When 25 referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally 30 effective unit dosage forms such as tablets, pills and

- 11 -

capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or 5 pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope 10 over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers 15 or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel 20 compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut 25 oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl- 30 pyrrolidone or gelatin.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions

- 12 -

may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably 5 sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. 10 Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

For topical administration, for example as a cream, ointment or lotion, pharmaceutically acceptable 15 carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or arylalkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethylcellulose, polyvinylpyrrolidone, isopropyl 20 myristate and other conventionally-employed non-toxic, pharmaceutically acceptable organic and inorganic carriers. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents 25 and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non-injurious 30 in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium chloride, sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate,

- 13 -

polyoxyethylene sorbitan monopalmitate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetraacetic acid, and the like.

5 The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient.

10 The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such 15 as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as MS and ALS and other neuropathological 20 disorders such as peripheral neuropathy, including diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; small cell carcinomas such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion 25 such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and asthma, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such 30 as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis;

- 14 -

addiction disorders such as alcoholism; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosis; 5 gastrointestinal (GI) disorders and diseases of the GI tract such as disorders associated with the neuronal control of viscera such as ulcerative colitis, Crohn's disease and incontinence; emesis, including acute, delayed and anticipatory emesis, for example, induced by chemotherapy, radiation, toxins, pregnancy, vestibular disorders, surgery, migraine and variations in 10 intercranial pressure; disorders of bladder function such as bladder detrusor hyper-reflexia; fibrosing and 15 collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, 20 for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

The compounds of formula (I) are particularly useful in the treatment of pain or nociception and/or 25 inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

30 The present invention further provides a compound of formula (I), or a salt or prodrug thereof, for use in therapy.

In the treatment of conditions involving actions of tachykinins released physiologically in


- 15 -

response to noxious or other stimuli, a suitable dosage level is about 0.001 to 50 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be 5 administered on a regimen of 1 to 4 times per day, preferably once daily.

According to a further or alternative aspect, the present invention provides a method of treatment of a human or animal subject suffering from or susceptible to 10 a condition characterised by the presence of an excess of tachykinin which method comprises administering to a human or animal subject in need of such treatment an effective amount of a compound of formula (I), or a salt or prodrug thereof.

15 The present invention also provides the use of a compound of formula (I), or a salt or prodrug thereof, for the manufacture of a medicament for the treatment of conditions characterised by the presence of an excess of tachykinins.

20 Compounds of formula (I) may be prepared from intermediates of formula (II):



(II)

wherein Q¹, R³, R⁴, X, Y and --- are as defined for 30 formula (I), by reaction with a reagent suitable to introduce the group R².


Suitable reagents will be readily apparent to those skilled in the art and include, for example, carboxylic acids of formula R²-OH, acyl halides of

- 16 -

formula R^2 -Hal, where Hal is halo, such as chloro, bromo or iodo. The reaction is preferably conducted in the presence of a base, such as a tertiary amine, for example, triethylamine, conveniently in a suitable 5 organic solvent, such as, for example, dimethyl formamide.

Acids and acyl halides of formulae R^2 -OH and R^2 -Hal are commercially available or may be prepared by conventional methods, for example, as described in the 10 accompanying examples or in Helv. Chim. Acta, 57, 2332 (1974).

Intermediates of formula (II) wherein X and Y together represent =O and the double bond is present may be prepared by reaction of an aldehyde of formula R^4 CHO 15 with a compound of formula (III):



(III)

wherein Q^1 , R^1 and R^3 are as defined for formula (I) and 25 R^{20} represents a group PR^X_3 or $PO(OR^X)_2$, wherein R^X represents phenyl or C_{1-10} alkyl, in the presence of a base.

Suitable bases include alkali metal hydrides, such as, for example, sodium hydride, alkali metal 30 carbonates, such as, for example, potassium carbonate, and strong organic bases such as, for example, 1,8-diazabicyclo[5.4.0] undec-7-ene in the presence of anhydrous lithium chloride.

- 17 -

The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, or acetonitrile, suitably at ambient temperature.

5 Compounds of formula (II) wherein one of X and Y represents H and the other represents hydroxy may be prepared from the corresponding compounds of formula (II) wherein X and Y together represent =O, by reduction.

10 Suitable reducing agents include, for example, hydride reducing agents such as lithium aluminium hydride and sodium borohydride.

The reaction is conveniently carried out in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, suitably at ambient temperature.

15 Compounds of formula (II) wherein one of X and Y represents H and the other represents C₁-6alkoxy may be prepared from the corresponding compounds of formula (II) wherein one of X and Y represents H and the other represents hydroxy, by alkylation.

20 Suitable alkylation procedures include treatment of an alcohol of formula (II) with an alkali metal hydride, such as sodium hydride, and a C₁-6alkylhalide. Suitable halides include, in particular, bromides and iodides.

25 The reaction is conveniently effected in an anhydrous organic solvent, for example, an ether, e.g. dimethoxyethane, suitably at ambient temperature.

30 Compounds of formula (II) wherein X and Y together represent =NOR⁵ may be prepared from the corresponding compounds of formula (II) wherein X and Y together represent =O by the addition of hydroxylamine, or a derivative thereof. Compounds wherein R⁵ is other than H may be prepared from the corresponding compounds wherein R⁵ is H by alkylation, for example, using a diazo

- 18 -


compound, such as diazomethane, or an alkyl halide or sulphate.

Compounds of formula (II) wherein the double bond is absent may be prepared from the corresponding 5 unsaturated compounds of formula (II) by reduction.

Suitable reduction procedures include catalytic 10 hydrogenation. Suitable hydrogenation catalysts include nobel metals, for example, platinum or palladium, or oxides thereof, which may be supported, for example, on charcoal. A preferred catalyst is Wilkinson's catalyst 15 (tris(triphenylphosphine)rhodium(I)chloride).

The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, an alcohol, e.g. ethanol, or an ester, 15 e.g. ethyl acetate, suitably at ambient temperature.

Compounds of formula (III) may be prepared from 20 compounds of formula (IV)



(IV)

wherein Q¹, R¹ and R³ are as defined for formula (I) and R²¹ represents an alkoxy or a suitably substituted amino group, such as a group NR²YOR³, where R² and R³ represent 30 alkyl, in particular a group NCH₃(OCH₃), by reaction with a compound of formula CH₃PO(OR⁴)₂, where R⁴ is an alkyl group, in the presence of a base.

- 19 -

Suitable reaction procedures will be readily apparent to the skilled person and examples thereof are described in the accompanying Examples.

Suitable bases of use in the reaction include 5 alkyl lithiums, such as butyl lithiums.

Compounds of formula (IV) are commercially available or may be prepared using standard procedures well known to the skilled person in the art. The compounds of formula (IV) are amino acid derivatives. 10 Syntheses of amino acids and derivatives thereof are well documented and are described, for example, in Chemistry and Biochemistry of the Amino Acids, ed. G. C. Barrett, Chapman and Hall, 1985.

Where the above-described processes for the 15 preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated, suitably by conventional techniques such as preparative chromatography.

The novel compounds may be prepared in racemic 20 form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with 25 an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, 30 followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This

- 20 -

may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The 5 protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following non-limiting Examples illustrate the preparation of compounds according to the invention.

EXAMPLE 1: 5-(3,5-Bis(trifluoromethyl)phenyl)-1-(3-indolyl)-2-((N-morpholinyl) acetamido)-3-pantanone Hydrochloride

(a) N-Methoxy-N-methyl-2-t-butyloxycarbonylamino-3-(3-indolyl) propionamide

5 N- δ -BOC-L-tryptophan (100g) was dissolved in dimethyl formamide (800ml) and triethylamine (101g) was added. The reaction was cooled to -30°C and isobutyl chloroformate (42.5ml) was added, maintaining the internal temperature to below -20°C. The reaction was stirred for 15 minutes before adding
10 N,O-dimethyl hydroxylamine hydrochloride (64g) and then diluting the reaction with dichloromethane (1l), maintaining the internal temperature below 0°C. The reaction was stirred for 15 minutes, poured into ethyl acetate (3l) and washed with 10% citric acid (1l), water (3x 1l), saturated sodium bicarbonate (1l) and water (1l). The organic phase was dried ($MgSO_4$), filtered, and evaporated until crystallisation ensued. The suspension was diluted with petroleum ether, filtered and dried to yield the title compound; mp = 129-130°C; 1H NMR (360MHz, D_6 DMSO) δ 10.80 (1H, s); 7.51 (1H, d, J = 7Hz); 7.33 (1H, d, J = 7Hz); 7.16 (1H, s); 7.08-6.97 (3H, m); 4.62-4.58 (1H, m); 3.72 (3H, s); 3.34 (3H, s); 3.02-2.81 (2H, m); 1.31 (9H, s).

(b) 2-t-Butyloxycarbonylamino-1-(3-indolyl)-4-dimethylphosphono-3-butanone

25 Dimethyl methane phosphonate (205g) was dissolved in tetrahydrofuran (800ml), cooled to -70°C; and then treated with n-butyllithium (1.6M in hexane, 900ml), maintaining the internal temperature of the reaction at below -55°C. The reaction was stirred for one hour before adding the product of part (a) (90g). The reaction was stirred at -70°C for 30 minutes
30 before quenching with saturated ammonium chloride. The resulting mixture was extracted with ethyl acetate and the

organic extract was washed with water (5 x 500ml), dried (MgSO₄) and evaporated. The residue was purified on silica (eluting with ethyl acetate) to yield the title compound as an oil; ¹H NMR (360MHz, CDCl₃) δ10.84 (1H, s), 7.56 (1H, d, J = 7Hz), 7.33 (1H, d, J = 7Hz), 6.98 (1H, t, J = 7Hz), 4.34-4.31 (1H, m), 3.63 (6H, d, J = 11Hz), 3.39 (2H, d, J = 22Hz), 3.19-3.11 (1H, m), 2.91-2.84 (1H, m); found: C, 55.73, H, 6.34; N, 6.80; C₁₉H₂₇N₂O₆P requires C, 55.60; H, 6.63; N, 6.82%.

5 (c) 5-(3,5-Bistrifluoromethylphenyl)-2-t-

10 butyloxycarbonylamino-1-(3-indolyl)-4-penten-3-one

A solution of the product of part (b) (69.0g) in acetonitrile (600ml) was stirred with diisopropylethylamine (43.3g), and anhydrous lithium chloride (14.13g) for 30 minutes before adding 3,5-bistrifluoromethylbenzaldehyde (55g) in acetonitrile (200ml). The reaction was stirred for two hours then the solvent was removed and the residue partitioned between ethyl acetate and water. The organic phase was washed with 10% citric acid (500ml), water (500ml), saturated sodium bicarbonate (500ml) and water (500ml). The solution was dried (MgSO₄), filtered and evaporated. The residue was purified by column chromatography on silica using ethyl acetate/petroleum ether (1:4) to yield the title compound as a pale yellow solid, mp = 137-138°C; found: C, 59.23; H, 4.79; N, 5.35; C₂₆H₂₄F₆N₂O₃ requires C, 59.32; H, 4.60; N 5.32%.

25 (d) 5-(3,5-Bistrifluoromethylphenyl)-2-t-

butyloxycarbonylamino-1-(3-indolyl)-3-pentanone

The product of part (c) was heated under reflux with tri-n-butyltin hydride (51.12g) in toluene for 20 hours. The reaction was cooled and purified by column chromatography on silica using ethyl acetate/petroleum ether (1:4) to yield the title compound as a white solid (37.1g), mp = 138-140°C: found: C,

59.23; H, 4.90; N, 5.28; $C_{26}H_{24}F_6N_2O_3$ requires C, 59.09, H, 4.96; N, 5.30%.

5 (e) 2-Amino-5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-3-pentanone Hydrochloride

10 The product of part (d) was treated with ethereal hydrogen chloride for one hour. The precipitated white solid was filtered and dried, mp = 84-86°C; found: C, 54.40; H, 4.25; N, 6.10; $C_{21}H_{18}F_6N_2O \cdot HCl$ requires C, 54.26; H, 4.12; N, 6.03%.

15 (f) 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(N-morpholinyl) acetamido-3-pentanone Hydrochloride

20 Potassium 2-(N-morpholinyl) acetate (0.2g) and triethylamine (0.1g) were dissolved in dry dimethylformamide and cooled to -30°C before adding isobutylchloroformate (0.147g). The reaction was stirred for 20 minutes before adding the product of example 1(e). The reaction was stirred for 3 hours, poured into water and then partitioned between ethyl acetate and water. The organic phase was washed with water (100ml), sodium bicarbonate (100ml) and water (100ml). The organic extract was dried ($MgSO_4$), filtered and evaporated. The residue was purified by column chromatography on silica using ethyl acetate. The resulting oil was treated with ethereal hydrogen chloride to yield the title compound as a white solid, mp = 83-86°C; found: C, 53.67; H, 4.89; N, 6.86 $C_{27}H_{27}F_6N_3O_3 \cdot HCl$. 0.5 H_2O requires C, 53.96; H, 4.86; N, 6.99%.

25 EXAMPLE 2: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-pyridyl)acetamido)-3-pentanone Hydrochloride

30 4-Pyridylacetic acid (210mg) was suspended in a solution of triethylamine (234mg) in dimethylformamide (4ml) and dichloromethane (5ml). Carbonyl diimidazole (196mg) was added to the suspension and stirred for 0.5 hours before adding

the compound of Example 1(e) (500mg). The reaction was stirred for 12 hours, poured into ethyl acetate and washed with water. The organic layer was dried ($MgSO_4$), evaporated and purified by silica chromatography using dichloromethane/methanol (98:2). The oil obtained was treated with ethereal hydrogen chloride to yield the title compound as a solid, mp = 88-90°C; found: C, 55.79; H, 4.40; N, 6.78 $C_{28}H_{23}F_6N_3O_2 \cdot HCl \cdot H_2O$ requires C, 55.87; H, 4.35; N, 6.98%.

10 EXAMPLE 3: 5-(3,5-Bistrifluoromethylphenyl)-2-((4-imidazolyl)acetamido)-1-(3-indolyl)-3-pantanone Hydrochloride

Prepared from the compound of Example 1(e) in a similar manner to Example 2 using imidazole-4-acetic acid to give the title compound as a white solid, mp = 103-106°C; found: C, 51.95; H, 4.33; N, 9.29; $C_{26}H_{22}F_6N_4O_2 \cdot HCl \cdot 1.5 H_2O$ requires C, 52.05; H, 4.37; N, 9.34%.

15 EXAMPLE 4: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-((3-pyridyl)acetamido)-3-pantanone Hydrochloride

20 Prepared from the compound of Example 1(e) in a similar manner to Example 2 using 3-pyridylacetic acid to give the title compound as a solid, mp = 90 - 92°C; found: C, 56.48; H, 4.47; N, 7.10; $C_{28}H_{23}F_6N_3O_2 \cdot HCl \cdot 0.5 H_2O$ requires C, 56.72; H, 4.25; N, 7.09%.

25 EXAMPLE 5: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-((2-pyridyl)acetamido)-3-pantanone Hydrochloride

Prepared from the compound of Example 1(e) in a similar manner to Example 2 using 2-pyridylacetic acid to give the title compound as a solid, mp = 92 - 94°C; found: C, 56.72; H, 4.35; N,

- 25 -

6.91; $C_{28}H_{23}F_6N_3O_2 \cdot HCl \cdot 0.5 H_2O$ requires C, 56.72; H, 4.25
N, 7.09%.

EXAMPLE 6: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-
(4-methyl piperazinyl)acetamido)-3-pantanone Hydrochloride

5 Prepared from the compound of Example 1(e) in a similar
manner to Example 1(f) using potassium 2-(4-methylpiperazinyl)
acetate to give the title compound as a white solid, mp = 120 -
122°C; found: C, 49.35; H, 5.04; N, 8.09; $C_{28}H_{30}F_6N_4O_2 \cdot 2 HCl$.
10 $2H_2O$ requires C, 49.64; H, 5.36; N, 8.27%.

EXAMPLE 7: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-
(quinuclidine-4- carboxamido)-3-pantanone Hydrochloride

15 Quinuclidine-4-carboxylic acid (Helv. Chim Acta, 57, 2332,
(1974)) (110mg) was heated with thionyl chloride (2ml) for 2
hours. The solvent was removed and the residue was azeotroped
with toluene (3 x 10ml) and then dissolved in dichloromethane
(10ml). The compound of Example 1(e) (325ml) was dissolved in
a mixture of dichloromethane (10ml) and triethylamine (200mg)
20 and added to the above solution. The reaction was stirred for 1
hour, poured into ethyl acetate and washed with potassium
carbonate solution. The organic solution was dried, evaporated
and purified by alumina chromatography using
dichloromethane/methanol (99:1). The oil obtained was treated
25 with ethereal hydrogen chloride to yield the title compound as a
white solid mp = 183 - 184°C; found: C, 55.97; H, 5.25; N, 6.85;
 $C_{29}H_{29}F_6N_3O_2 \cdot HCl \cdot H_2O$ requires C, 56.18; H, 5.20; N, 6.78%.

EXAMPLE 8: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-
(3-(piperidin-1-yl) propionamido)-3-pantanone

Prepared from the compound of Example 1(e) in a similar manner to Example 7 using 1-piperidinopropionic acid and obtained as a white solid, mp 141°C; found: C, 61.26; H, 5.46; N, 7.35. $C_{29}H_{31}N_3O_2F_6$ requires C: 61.37; H, 5.50; N, 7.40.

5

EXAMPLE 9: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(3-(3-azabicyclo[3.2.2]nonyl)butyramido)-3-pentanone Hydrochloride

10

a) Ethyl-4-(3-(3-azabicyclo[3.2.2]nonyl))butyrate

15

To a solution of 3-azabicyclo[3.2.2]nonane (0.5g) in tetrahydrofuran (5ml) was added triethylamine (0.61ml) followed by ethyl 4-bromobutyrate (0.63ml). The solution was stirred for 16 hours under reflux, cooled and concentrated in vacuo. The residue was partitioned between ethyl acetate and water and the organic solution separated, dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel eluting with diethyl ether-petroleum ether (1:9) to give the title compound.

20

b) 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(3-(3-azabicyclo[3.2.2]nonyl))butyramido)-3-pentanone Hydrochloride

25

To a solution of the product of part a) (0.67g) in water (3ml) and ethanol (1.5ml) was added 2N sodium hydroxide solution (1.4ml). The solution was heated under reflux for 2 hours then cooled and adjusted to pH1 with dilute hydrochloric acid. The solution was freeze dried and the resulting solid added to dimethylformamide (15ml) containing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.54g). After stirring for 30 minutes at 0°C, a solution of 5- (3, 5- bistrifluoromethylphenyl) -1-(3- indolyl) -2-amino-3- pentanone hydrochloride and triethylamine (0.3ml) in dimethylformamide (5ml) was added and stirred for 16 hours at 25°C. Ethyl acetate was added and the solution washed with water (3x),

5 dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel eluting with methanol-dichloromethane (1:19) then treated with ethereal hydrogen chloride to give the title compound, mp 101-104°C; found: C, 56.90; H, 5.95; N, 5.67. $\text{C}_{33}\text{H}_{37}\text{F}_6\text{N}_3\text{O}_2 \cdot \text{HCl} \cdot 2\text{H}_2\text{O}$ requires C, 57.09; H, 6.09; N, 6.05.

10 EXAMPLE 10: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-benz[b]thienyl)-2-((4-pyridyl)acetamido)-3-pentanone
10 a) 3-(3-Benz[b]thienyl)-2-t-butyloxycarbonylamino propionic acid

15 2-Amino-3-(3-benz[b]thienyl)propionic acid (Int. J. Peptide Protein Res., (1987), **29**, 118) (22.9g) and sodium carbonate (27.6g) were added to a mixture of water (350ml) and 1,4-dioxane (150ml). Di-t-butyldicarbonate (34.1g) was added to the mixture and the reaction was stirred for 16 hours and washed with ether (500ml). The reaction mixture was acidified to pH3 with solid citric acid and extracted with ethyl acetate to yield the title compound (31.5g).

20 b) Methyl 3 - (3- benzo [b] thienyl) - 2-t - butyloxy carbonyl amino propionate

25 The product of Example 9(a) (31.5g) and Cesium carbonate (15.93g) were dissolved in methanol and the solvent was removed by evaporation. The residue was dissolved in dimethylformamide and iodomethane (27.8g) was added. The reaction was stirred for 16 hours then the solvent was removed and the residue partitioned between ethyl acetate and water. The organic extract was washed with sodium bicarbonate solution and water, dried (MgSO_4), and evaporated. The residue was purified by column chromatography on silica using ethyl acetate/petroleum ether (1:4) to yield the title compound (27.3g).

c) 5-(3,5-Bistrifluoromethylphenyl)-1-(3-benzothienyl)-2-((4-pyridyl)acetamido)-3-pentanone

Prepared by the methods of Examples 1(b)-1(e) and 2 starting with the compound of Example 10(b) instead of the compound of Example 1(a). Mp 184-187°C; found: C, 56.06; H, 4.03; N, 4.77. $C_{28}H_{22}F_6N_2O_2S$. HCl requires C, 55.96; H, 3.86; N, 4.66.

10 EXAMPLE 11: 5-(3,5-Bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-2-((4-pyridyl)acetamido)-3-pentanone

Prepared by the method of Example 10 starting with 3,4-dichlorophenylalanine. Mp 142-144°C; found: C, 49.96; H, 3.63; N, 4.36. $C_{26}H_{20}Cl_2F_6N_2O_2$. HCl. 0.5 H_2O requires C, 50.14; H, 3.56; N, 4.50.

15 EXAMPLE 12: 5-(3,5-Bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-2-(quinuclidine-4-carboxamido)-3-pentanone Hydrochloride

Prepared by the methods of Examples 7 and 14. Mp 50-530°C; found: C, 49.89; H, 4.53; N, 4.30. $C_{27}H_{26}Cl_2F_6N_2O_2$. HCl. H_2O requires C, 49.90; H, 4.50; N, 4.37.

20 EXAMPLE 13: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-pyridyl)acetamido)-3-oximinopentane

The compound of Example 2 (1.0g) in methanol (20ml) was treated with hydroxylamine hydrochloride (0.5g) and sodium acetate (1.5g) for 16 hours. The solution was concentrated in vacuo and the residue partitioned between ethyl acetate and water. The ethyl acetate solution was separated, dried and concentrated and the residue crystallised from ethyl

acetate/petroleum ether to give the title compound, mp 196-198°C. Found: C, 59.87; H, 4.39; N, 9.93. $C_{28}H_{24}F_6N_4O_2$ requires C, 59.79; H, 4.30; N, 9.96.

5 **EXAMPLE 14: 5-(3,5-Bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-2-4-(3-(3-azabicyclo[3.2.2]nonyl)butyramido)-3-pentanone Hydrochloride**

Prepared by the methods of Examples 9 and 14.

Mp 90-93°C. Found: C, 51.58; H, 5.42; N, 3.83.

10 $C_{31}H_{34}Cl_2F_6N_2O_2 \cdot HCl \cdot 2H_2O$ requires C, 51.43; H, 5.43; N, 3.87.

EXAMPLE 15: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-pyridyl)acetamido)-3-pentanol

15 A solution of the compound of Example 2 (360mg) in ethanol (10ml) was treated with sodium borohydride (100mg) for 1 hour. The solution was concentrated *in vacuo* and the residue partitioned between ethyl acetate and ammonium chloride solution. The organic solution was dried and evaporated to give a white solid. Crystallisation from ethyl acetate-diethyl ether gave the title compound as a single diastereomer, mp 213-214°C; found: C, 60.97; H, 4.58; N, 7.47. $C_{28}H_{25}F_6N_3O_2$ requires C, 61.20; H, 4.59; N, 7.65.

20 Further crystallisation of the mother liquors from above gave the title compound as a mixture of diastereomers.

EXAMPLE 16: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(1-pyrrolidinyl)butyramido)-3-pentanone

25 The title compound was prepared from pyrrolidine-1-butric acid and the compound of Example 1c) using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride as

- 30 -

coupling agent by the method of Example 9. Mp 99-100°C; found: C, 61.70; H, 5.48; N, 7.36. $C_{29}H_{31}F_6N_3O_2$ requires C, 61.37; H, 5.51; N, 7.40.

5 **EXAMPLE 17: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(4-morpholinyl)butyramido)-3-pentanone Hydrochloride**

Prepared by the method of Example 16 using 4-morpholine butyric acid. Mp 64-65°C; found: C, 53.84; H, 5.44; N, 6.32. $C_{29}H_{31}F_6N_3O_2 \cdot HCl \cdot 1.5H_2O$ requires C, 53.83; H, 5.45; N, 6.49.

10 **EXAMPLE 18: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(3-pyridyl)acrylamido)-3-pentanone**

15 Prepared by the method of Example 16 using 3-(3-pyridyl)acrylic acid. Mp 138-139°C; found: C, 62.66; H, 4.01; N, 7.54. $C_{29}H_{23}F_6N_3O_2$ requires C, 62.25; H, 4.14; N, 7.51.

20 **EXAMPLE 19: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(3-pyridyl)propionamido)-3-pentanone**

25 A solution of 3-pyridylacrylic acid (900mg) in ethanol (30ml) was shaken under hydrogen gas at 30 psi for 2.5 hours over 10% Pd-C (100mg). The solution was filtered and concentrated under reduced pressure to give a colourless solid which was dried under high vacuum. The resulting solid with the compound of Example 1e), by the method of Example 7, gave the title compound, mp 123-124°C; found: C, 62.11; H, 4.16; N, 7.25. $C_{29}H_{23}F_6N_3O_2$ requires C, 62.03; H, 4.49; N, 7.48.

30 **EXAMPLE 20: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-pyridyl)acrylamido)-3-pentanone Hydrochloride**

a) 4-pyridylacrylic acid

A mixture of potassium carbonate (22g), triethylphosphonoacetate (22.6ml) and 4-pyridylcarboxaldehyde (11g) in tetrahydrofuran (110ml) was heating under reflux for 3 hours under an atmosphere of argon. The reaction was cooled, 5 diluted with ethyl acetate, washed with water, dried (K_2CO_3) and concentrated *in vacuo*. The residue was diluted with petroleum ether and the resulting solid filtered and dried *in vacuo*. A solution containing a portion of the foregoing solid (2.1g) in tetrahydrofuran (15ml) and 4N aqueous sodium 10 hydroxide (20ml) was stirred for 16 hours. Ethyl acetate (30ml) was added followed by acetic acid until the aqueous solution reached pH 7. The ethyl acetate solution was separated, dried ($MgSO_4$) concentrated and the residue crystallised from diethyl ether-petroleum ether to give the title compound.

15 b) 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-pyridyl)acrylamido)-3-pentanone Hydrochloride

Prepared from 4-pyridylacrylic acid by the method of Example 16. Mp 122-126°C; found C, 58.08; H, 3.92; N, 6.79. $C_{29}H_{23}F_6N_3O_2 \cdot HCl$ requires C, 58.45; H, 4.06; N, 7.05.

20 EXAMPLE 21: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-pyridyl)propionamido)-3-pentanone

25 4-Pyridylacrylic acid was hydrogenated by the method of Example 19 and reacted with the compound of Example 1e) by the method of Example 16 to give the title compound, mp 108°C; found: C, 61.89; H, 4.31; N, 7.28. $C_{29}H_{25}F_6N_3O_2$ requires C, 62.03; H, 4.49; N, 7.48.

30 EXAMPLE 22: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-piperidinyl)propionamido)-3-pentanone Hydrochloride
a) 3-(4-(1-Butyloxycarbonyl)piperidinyl) propionic acid

To a solution of ethyl isonipecotate (17.1g) in dichloromethane (60ml) at 4°C was added di-*t*-butyldicarbonate (24g) with stirring. After 10 minutes the solvent was removed under reduced pressure and the residue dried under high 5 vacuum, then dissolved in dichloromethane (100ml). To this solution, under an atmosphere of argon at -78°C, was added diisobutyl aluminum hydride (110ml of a 1.0M solution in toluene). After stirring for 1 hour, 2N hydrochloric acid (55ml) was added dropwise and the mixture allowed to warm to 20°C, 10 then diluted with ethyl acetate. The ethyl acetate solution was separated off, dried (K_2CO_3) and concentrated. The resulting residue was reacted with triethylphosphonoacetate and then sodium hydroxide by the method of Example 20a), then 15 hydrogenated by the method of Example 19 to give the title compound which was crystallised from hot petroleum ether (bp 60-80°C).

b) 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-piperidinyl)propionamido)-3-pentanone Hydrochloride

The compound of part a) (476mg) in dry benzene (5ml) was 20 treated with oxalyl chloride (0.16ml) until evolution of gas ceased. The solution was concentrated *in vacuo* and dissolved in dichloromethane (10ml) with the compound of Example 1e) (740mg) and triethylamine (0.56ml). After stirring 1 hour aqueous sodium bicarbonate was added and the mixture 25 extracted with dichloromethane which was then dried (Na_2SO_4) and concentrated. The residue was purified by chromatography on silica gel (eluant ethyl acetate-petroleum ether 2:3) then treated with ethereal hydrogen chloride for 16 hours. After 30 removal of the solvent under reduced pressure, trituration with diisopropyl ether gave the title compound, mp 124-126°C; found:

C, 57.31; H, 5.55; N, 6.53. $C_{29}H_{31}F_6N_3O_2 \cdot HCl$ requires C, 57.66; H, 5.34; N, 6.96.

EXAMPLE 23: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-piperidinecarboxamido)-3-pentanone Hydrochloride

5 The compound of Example 1e) was reacted with N-butoxycarbonylnipecotic acid by the method of Example 2. The resulting material was treated with ethereal hydrogen chloride for 16 hours then concentrated and crystallised from methanol-10 ethyl acetate to give the title compound, mp 209-213°C; found: C, 55.82; H, 4.75; N, 6.89. $C_{27}H_{27}F_6N_3O_2 \cdot HCl \cdot 0.25H_2O$ requires C, 55.87; H, 4.95; N, 7.24.

EXAMPLE 24: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(1-piperazinyl)ureido)-3-pentanone

15 The compound of Example 1(c) (400mg) in tetrahydrofuran (10ml) was treated with triethylamine (0.12ml) and 4-nitrophenylchloroformate (174mg) for 1 hour. The solvent was removed *in vacuo* and the residue partitioned between ethyl acetate and water. The organic solution was dried (Na_2SO_4) and concentrated to give a solid which was dissolved in dichloromethane (15ml). *t*Butyl-1-piperazine carboxylate (156mg) was added and the solution stirred under an atmosphere of nitrogen overnight. The reaction was diluted with dichloromethane, washed with water, dried (Na_2SO_4) and concentrated to give an oil which was purified by chromatography on silica gel eluting with ethyl acetate-petroleum ether (1:1). The resulting product was treated with ethereal hydrogen chloride for 16 hours then the solution was evaporated and the residue crystallised from diethyl ether-petroleum ether to give the title compound, mp 120-122°C;

found: C, 51.86; H, 4.97; N, 8.85. $C_{26}H_{26}F_6N_4O_2 \cdot HCl \cdot 1.5H_2O$
requires C, 51.70; H, 5.00; N, 9.27.

5 EXAMPLE 25: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-pyridinecarboxamido)-3-pentanone

The title compound was prepared using pyridine-4-carboxylic acid by the method of Example 9(b). Mpt 72-74°C; found: C, 59.63; H, 4.06; N, 7.62. $C_{27}H_{21}F_6N_3O_2 \cdot 0.5H_2O$ requires C, 59.78; H, 4.09; N, 7.75.

10

EXAMPLE 26: 5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-2-(2-(N-(3,4-pyridinedicarboximido)acetamido)-3-pentanone

15 The title compound was prepared using N-carboxymethyl-3,4-pyridinedicarboximide by the method of Example 9(b). Mpt 144-145°C; found: C, 58.64; H, 3.57; N, 8.69. $C_{30}H_{22}F_6N_4O_4$ requires C, 58.45; H, 3.60; N, 9.09.

- 35 -

The following examples illustrate pharmaceutical compositions according to the invention.

EXAMPLE 27A Tablets containing 1-25mg of compound

		<u>Amount mg</u>		
5	Compound of formula (I)	1.0	2.0	25.0
	Microcrystalline cellulose	20.0	20.0	20.0
	Modified food corn starch	20.0	20.0	20.0
	Lactose	58.5	57.5	34.5
10	Magnesium Stearate	0.5	0.5	0.5

EXAMPLE 27B Tablets containing 26-100mg of compound

		<u>Amount mg</u>		
15	Compound of formula (I)	26.0	50.0	100.0
	Microcrystalline cellulose	80.0	80.0	80.0
	Modified food corn starch	80.0	80.0	80.0
	Lactose	213.5	189.5	139.5
	Magnesium Stearate	0.5	0.5	0.5

20 The compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active compound per tablet.

EXAMPLE 28 Parenteral injection

		<u>Amount mg</u>
30	Compound of formula (I)	1 to 100mg
	Citric Acid Monohydrate	0.75mg
	Sodium Phosphate	4.5mg
	Sodium Chloride	9mg
	Water for Injections	to 1ml

- 36 -

The sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water. The compound of formula (I) is dissolved or suspended in the solution and made up to volume.

5

EXAMPLE 29 Topical formulation


	<u>Amount mg</u>
Compound of formula (I)	1-10g
Emulsifying Wax	30g
10 Liquid paraffin	20g
White Soft Paraffin	to 100g
15	The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.

- 37 -

CLAIMS:

1. A compound of formula (I):

5



(I)

15 wherein

Q¹ represents a phenyl group substituted by one or more halo; optionally substituted naphthyl; optionally substituted indolyl; optionally substituted benzthiophenyl; optionally substituted benzofuranyl; optionally substituted benzyl; or optionally substituted fluorenyl;

20 the dotted line represents an optional covalent bond;

25 one of X and Y represents H and the other of X and Y represents hydroxy or C₁-6alkoxy, or X and Y together form a group =O or =NOR⁵ where R⁵ is H or C₁-6alkyl;

30 R¹ represents H or C₁-6alkyl.

R² represents CO-W-R⁶ where W represents a bond or a saturated or unsaturated hydrocarbon chain of 1, 2, 3, 4, 5 or 6 carbon atoms and R⁶ is an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group;

R³ represents H, C₁-6alkyl or C₂-6alkenyl; and

- 38 -

R^4 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_1 - 6 alkyl, C_2 - 6 alkenyl, C_2 - 6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, 5 CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_1 - 6 alkyl, phenyl or trifluoromethyl; or a salt of prodrug thereof.

2. A compound as claimed in claim 1 wherein 10 R^2 represents $CO(CH_2)_qR^6$ where q is 0, 1, 2, 3, 4, 5 or 6 and R^6 is as defined for formula (I).

3. A compound as claimed in claim 1 or claim 15 2 wherein Q^1 is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl.

4. A compound as claimed in any preceding claim wherein the optional covalent bond is absent.

20 5. A compound as claimed in any preceding claim wherein one of X and Y is H and the other of X and Y is C_1 - 6 alkoxy; or X and Y together from a group =O.

25 6. A compound as claimed in any preceding claim wherein R^1 is H.

7. A compound as claimed in any preceding claim wherein R^6 is imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, 30 pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl, indolyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorbornanyl, pyridosuccinimido, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl.

- 39 -

8. A compound as claimed in claim 7 wherein
R⁶ is imidazolyl, pyridyl, morpholinyl, piperazinyl,
methylpiperazinyl, piperidinyl, pyrrolidinyl,
5 3,4-pyridinecarboximido, azabicyclo[2.2.2]octanyl or
azabicyclo[3.2.2]nonyl.

9. A compound as claimed in any preceding
claim wherein R⁴ represents phenyl substituted by 1 or 2
10 groups selected from C₁-4alkyl, halo and trifluoromethyl.

10. A compound as claimed in claim 1 selected
from:
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((N-
15 morpholinyl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-
pyridyl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-2-((4-
imidazolyl)acetamido)-1-(3-indolyl)-3-pentanone;
20 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((3-
pyridyl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((2-
pyridyl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-
25 methylpiperazin-1-yl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-
((quinuclidinyl-4-carboxamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-
30 (piperidin-1-yl)propionamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(3-
(3-azabicyclo[3.2.2]nonyl)butyramido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-benzo(b)thienyl)-2-
(4-pyridyl)acetamido)-3-pentanone;

- 40 -


5-(3,5-bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-
2-((4-pyridyl)acetamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-
2-(quinuclidine-4-carboxamido)-3-pentanone;
5 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-
pyridyl)acetamido)-3-oximinopentane;
5-(3,5-bistrifluoromethylphenyl)-1-(3,4-dichlorophenyl)-
2-(4-(3-(3-azabicyclo[3.2.2]nonyl)butyramido)-3-
pentanone;
10 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-((4-
pyridyl)acetamido)-3-pentanol;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(1-
pyrrolidinyl)butyramido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-(4-
15 morpholinyl)butyramido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(3-
pyridyl)acrylamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(3-
pyridyl)propionamido)-3-pentanone;
20 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-
pyridyl)acrylamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-
pyridyl)propionamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(4-
25 piperidinyl)propionamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-
piperidinecarboxamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(3-(1-
piperazinyl)ureido)-3-pentanone;
30 5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(4-
pyridinecarboxamido)-3-pentanone;
5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-2-(2-(N-
(3,4-pyridinecarboximido)acetamido)-3-pentanone;
and salts and prodrugs thereof.

- 41 -

11. A compound as claimed in any preceding claim for use in therapy.

5 12. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 10 in association with a pharmaceutically acceptable carrier.

10 13. A process for the preparation of a compound as claimed in claim 1 which process comprises reacting a compound of formula (II):



(II)

wherein Q^1 , R^1 , R^3 , R^4 , X , Y and --- are as defined for formula (I) with a reagent suitable to introduce the group R^2 , and optionally forming a salt or prodrug.

25 14. A method for the treatment or prevention of a physiological disorder associated with an excess of tachykinins, which method comprises administration to a patient in need thereof of a tachykinin-reducing amount of a compound according to claim 1.

30 15. A method according to claim 14 for the treatment or prevention of pain or inflammation.

- 42 -

16. A method according to claim 14 for the treatment or prevention of migraine.

5 17. A method according to claim 14 for the treatment or prevention of arthritis.

10 18. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins.

15 19. The use of a compound as claimed in claim 1 for the manufacture of a medicament for the treatment of pain or inflammation.

20 20. A compound as claimed in any of claims 1 to 10 when prepared by the process of claim 10.

21. A process for preparing a composition as claimed in claim 12 which process comprises bringing a compound as claimed in any of claims 1 to 10 into association with a pharmaceutically acceptable carrier or excipient.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 93/01415

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC							
Int.C1. 5 C07D209/16; A61K31/33; C07D401/12; C07D403/12 C07D453/02; C07D221/22; C07D409/12; C07D213/56							
II. FIELDS SEARCHED Minimum Documentation Searched ⁷ <table border="1"> <tr> <th>Classification System</th> <th>Classification Symbols</th> </tr> <tr> <td>Int.C1. 5</td> <td>C07D</td> </tr> </table>				Classification System	Classification Symbols	Int.C1. 5	C07D
Classification System	Classification Symbols						
Int.C1. 5	C07D						
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸							
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹							
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³					
A	EP,A,0 394 989 (FUJISAWA PHARMACEUTICAL CO., LTD.) 31 October 1990 cited in the application see claims	1,18					
A	EP,A,0 333 174 (FUJISAWA PHARMACEUTICAL CO., LTD.) 20 September 1989 see claims	1,18					
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified) "D" document referring to an oral disclosure, use, exhibition or other means "E" document published prior to the international filing date but later than the priority date claimed							
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family							
IV. CERTIFICATION							
1 Date of the Actual Completion of the International Search 13 SEPTEMBER 1993		Date of Mailing of this International Search Report 29.09.93					
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer VAN BIJLEN H.					

EPO	PRINCIPAL DIRECTORATE FOR SEARCHING	SUPPLEMENTAL SHEET B	File number: 57 77.011
RESTRICTION OF THE SUBJECT OF THE SEARCH			
II) CLAIMS INCURRING FEES (claims fees not paid) (EP)			
<p>Claims not searched:</p> 			
III) LACK OF UNITY OF INVENTION (EP, SA, SN, TO, RS)			
<p>Mention the different inventions by indicating the claims and, if necessary, the subject-matter (preliminary communication of lack of unity a priori for TO and RS):</p> <p>Subject searched:</p>			
<p>YES NO 1. Claims:</p>			
<p>YES NO 2. Claims:</p>			
<p>YES NO 3. Claims:</p>			
<p>YES NO 4. Claims:</p>			
<p>— The partial search report will be drawn up for the invention first mentioned in the claims (item 1.). — The search report will be drawn up for the inventions in respect of which search fees have been paid, consequently also for the invention first mentioned in the claims. Delete (YES or NO) whenever is not applicable.</p>			
III) MEANINGFUL SEARCH NOT POSSIBLE OR INCOMPLETE SEARCH (EP, SA, SN, TO, RS)			
<p>1. SUBJECT-MATTER EXCLUDED FROM PATENTABILITY (see for EP, SA, SN and RS list of non-patentable inventions overleaf; for TO check national circumstances):</p>			
<p><input type="checkbox"/> Meaningful search not possible on the basis of all claims</p>			
<p><input checked="" type="checkbox"/> Incomplete search</p>			
<p>Claims searched completely:</p>			
<p>Claims searched incompletely:</p>			
<p>Claims not searched: 14 - 17</p>			
<p><input checked="" type="checkbox"/> REMARK</p>			
<p>p. t. d.</p>			
<p>2. OBSCURITIES, INCONSISTENCIES, CONTRADICTIONS, LACK OF CONCISENESS, LACK OF READY COMPREHENSIBILITY (EP: Art. 64 EPC; SA: Art. 6 PCT)</p>			
<p>Reason:</p>			
<p><input type="checkbox"/> Meaningful search not possible on the basis of all claims</p>			
<p><input type="checkbox"/> Incomplete search</p>			
<p>Claims searched completely:</p>			
<p>Claims searched incompletely:</p>			
<p>Claims not searched:</p>			